Indivior PLC(INDV) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, the company achieved record net revenue of $1.24 billion, a 4% increase compared to the previous year, with SUBLOCADE net revenue reaching $856 million, reflecting a 13% increase year-over-year [5][19] - Adjusted EBITDA grew by 20% year-over-year to $428 million, with a margin improvement of 500 basis points [5][24] - Operating expenses are projected to not exceed $450 million in 2026, indicating a focus on cost management [5][10] Business Line Data and Key Metrics Changes - SUBLOCADE dispense volume grew by 12% year-over-year in Q4 and 7% for the full year, indicating strong demand for the product [12][20] - The company launched a direct-to-consumer campaign, "Move Forward in Recovery," which has shown early signs of success, including a 60% increase in branded online search volume [16][17] Market Data and Key Metrics Changes - The long-acting injectables (LAIs) market is experiencing growth, with the company reporting a category growth of approximately 18% in Q4 2025 [40][44] - The company maintains a market share in the mid-70s for SUBLOCADE, with new patient starts achieving all-time highs [13][34] Company Strategy and Development Direction - The company is executing phase two of the Indivior Action Agenda, focusing on accelerating SUBLOCADE growth and enhancing adjusted EBITDA and cash flow [8][28] - The capital deployment strategy includes managing debt, a $400 million share repurchase program, and evaluating business development opportunities for growth drivers [10][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's ability to accelerate growth in 2026, with expectations of mid-teens dispense unit growth for SUBLOCADE [9][41] - The company believes long-acting injectables remain underutilized, presenting significant growth opportunities [9][33] Other Important Information - The company eliminated a significant future liability by paying a $295 million obligation related to a legacy DOJ matter [6][7] - The company ended 2025 with gross cash and investments of $222 million, positioning itself well for future investments [26] Q&A Session Summary Question: Thoughts on LAI penetration and market share - Management believes there is significant opportunity for LAI penetration to grow from the current 9%, with potential analogs suggesting a range of 20%-30% [33][34] Question: Guidance assumptions for LAI market growth in 2026 - The guidance assumes mid-teen SUBLOCADE growth, with continued stabilization of market share [41][42] Question: Medicaid funding landscape impact on SUBLOCADE - Management is optimistic about Medicaid support for opioid use disorder treatments and believes growth opportunities exist regardless of funding fluctuations [51][52] Question: Shape of SG&A in 2026 and DTC spending - Management indicated that DTC spending is a priority, with a commitment to over-invest in patient education and engagement [51][53] Question: Contribution from the criminal justice system to SUBLOCADE guidance - The criminal justice segment is viewed as a strong opportunity for growth, contributing to the overall LAI category expansion [67]